Clinical Trial Update: AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for AK104 combined with concurrent chemoradiation in esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: The First Affiliated Hospital of University of South China | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN